Michael H. Davidson to ErbB Receptors
This is a "connection" page, showing publications Michael H. Davidson has written about ErbB Receptors.
Connection Strength
0.046
-
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer Chemother Pharmacol. 2016 Feb; 77(2):375-83.
Score: 0.027
-
The membrane-associated protein, supervillin, accelerates F-actin-dependent rapid integrin recycling and cell motility. Traffic. 2010 Jun; 11(6):782-99.
Score: 0.018